FDMTHIGH SIGNALFINANCIAL10-K

FDMT shows significant financial deterioration with cash reserves declining substantially from $149.3M to $60.2M while current liabilities increased over 50%.

The company burned through nearly $90M in cash over the period, representing a 60% decline in liquidity, which raises concerns about runway for this clinical-stage biotech company. The simultaneous increase in current liabilities to $44.0M creates additional pressure on the balance sheet and suggests potential cash flow challenges ahead.

Comparing 2026-03-18 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

FDMT's financial position weakened materially as cash and equivalents dropped from $149.3M to $60.2M, while current liabilities grew from $29.1M to $44.0M. Operating cash flow improved modestly to -$109.1M from -$134.6M, and operating losses narrowed slightly to -$159.5M, but these improvements were insufficient to offset the dramatic cash decline. The overall picture signals a biotech company facing mounting liquidity pressure despite some operational efficiency gains.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-85.8%
$3.8M→$536K

Capex reduced 85.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-59.7%
$149.3M→$60.2M

Cash declined 59.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Liabilities
Balance Sheet
+50.9%
$29.1M→$44.0M

Current liabilities surged 50.9% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+22.6%
$49.8M→$61.0M

Liabilities increased 22.6% — monitor debt-to-equity ratio and interest coverage.

Operating Cash Flow
Cash Flow
+18.9%
-$134.6M→-$109.1M

Operating cash flow grew 18.9% — strong conversion of earnings to cash, healthy business fundamentals.

Operating Income
P&L
+15.1%
-$187.8M→-$159.5M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+12.9%
-$160.9M→-$140.1M

Net income grew 12.9% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-18
PRIOR — 2025-02-28
ADDED
This number does not include 16,935,665 shares of common stock issuable upon the exercise of pre-funded warrants outstanding as of March 16, 2026 (which are immediately exercisable at an exercise price of $0.0001 per share of common stock, subject to beneficial ownership limitations).
These forward-looking statements concern our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition.
The following is a summary of the principal risks that could seriously harm our business, all of which are more fully described in Part I.
iii Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay or limit the scope of regulatory approval and commercialization, which could seriously harm our business.
Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by others, and the patent protection, prosecution and enforcement for some of our product candidates may be dependent on our licensors.
+7 more — sign up free →
REMOVED
This number does not include 3,075,000 shares of common stock issuable upon the exercise of pre-funded warrants outstanding as of February 26, 2025 (which are immediately exercisable at an exercise price of $0.0001 per share of common stock, subject to beneficial ownership limitations) sold in the registrant s public offering in February 2024.
Additionally, this number does not include 6,310,000 shares of our common stock issuable upon the exercise of pre-funded warrants outstanding as of February 26, 2025, (which are both immediately exercisable at an exercise price of $0.0001 per share of common stock, subject to beneficial ownership limitations) issued in exchange for 5,775,000 shares of our common stock in November 2024 and 535,000 shares of our common stock in December 2024, respectively.
See Note 13, Common Stock Warrants, to the Registrant s financial statements.
Our products are developed with customized and evolved adeno-associated virus ( AAV ) vectors invented from our proprietary synthetic vector discovery platform, Therapeutic Vector Evolution ( TVE ).
TVE was designed to invent AAV vectors with properties that overcome the limitations of conventional AAV vectors by applying the principles of directed evolution in non-human primate ( NHP ) models to select vectors that target tissues of diseases with high unmet need using routine routes of administration.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →